Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation b...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Amatangelo, Michael D., Quek, Lynn, Shih, Alan, Stein, Eytan M., Roshal, Mikhail, David, Muriel D., Marteyn, Benoit, Farnoud, Noushin Rahnamay, de Botton, Stephane, Bernard, Olivier A., Wu, Bin, Yen, Katharine E., Tallman, Martin S., Papaemmanuil, Elli, Penard-Lacronique, Virginie, Thakurta, Anjan, Vyas, Paresh, Levine, Ross L.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2017
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553578/
https://ncbi.nlm.nih.gov/pubmed/28588019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-779447
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires